Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 28, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On February 24, 2006, an increase in the notional allocation of Ordinary Share ADRs occurred at a price of $51.10 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: February 24, 2006.
- Transaction Price: $51.10 per share for GSK Ordinary Share ADRs.
- Event Type: Increase in notional allocation within the US Retirement Savings Plan.
- Participants: The notification lists specific allocations for Dr. J P Garnier (53), Mr. F Calhoun (19), Dr. R Greig (21), Mr. D Phelan (25), Dr. D Pulman (6), Mr. D Stout (44), Mr. C Viehbacher (8), and Dr. T Yamada (10).